Global Human Rabies Treatment - Market

Human Rabies Treatment - Comprehensive Study by Type (Vero Cell Rabies Vaccine, BHK, Chick Embryo Cell Rabies Vaccine, Others), Application (Pre-Exposure Prophylaxis, Post-Exposure Prophylaxis), Distribution Channel (Hospital pharmacies, Retail pharmacies, E-commerce) Players and Region - Global Market Outlook to 2027

Human Rabies Treatment - Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Human Rabies Treatment - Market Overview:
Rabies is a viral disease which spreads to humans from animals and infects our nerves and brain. Rabies disease is caused by lyssaviruses; a genus of viruses in the Rhabdoviridae family. Some of the symptoms of rabies disease are such as irritability, agitation, confusion, bizarre , or hallucinations, muscle spasms and unusual postures, seizures, and weakness or paralysis.

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Historical Period2017-2021
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Adopting of dogs as pets is a popular trend across the world

Market Growth Drivers:
Increasing number of patient demand for treatment increases

Challenges:
High cost treatment

Restraints:
Shortage of vaccines

Opportunities:
Rising awareness of diseases

Competitive Landscape:
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.
Some of the key players profiled in the report are Novartis (Switzerland), Sanofi-Pasteur (France), Hissen (China), Biological E Ltd. (India), Cadila Healthcare (India), Grifols S.A. (Spain), Kamada Ltd (Israel), Kedrion S.p.A. (Italy), Serum institute (India) and Chengda (United States). Additionally, following companies can also be profiled that are part of our coverage like Yisheng (China), Prcmise (United States) and VACN (United States). Considering Market by Distribution Channel, the sub-segment i.e. Hospital pharmacies will boost the Human Rabies Treatment - market.

Latest Market Insights:
On February 28, 2024, Dyadic International, Inc. entered into a strategic partnership agreement with Rabian BV, to develop affordable rabies prophylactics and vaccines using Dyadic’s C1 protein production platform.

In February 2021, for the first time pediatric trial on children was demonstrated safe for the treatment of rabies. This treatment, known as KEDRAB. This treatment is used at the age of 17.

What Can be Explored with the Human Rabies Treatment - Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Human Rabies Treatment - Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Human Rabies Treatment -
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Human Rabies Treatment - market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Human Rabies Treatment - market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufactures, Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities and Government and Private Research Organizations.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Vero Cell Rabies Vaccine
  • BHK
  • Chick Embryo Cell Rabies Vaccine
  • Others
By Application
  • Pre-Exposure Prophylaxis
  • Post-Exposure Prophylaxis
By Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • E-commerce

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing number of patient demand for treatment increases
    • 3.3. Market Challenges
      • 3.3.1. High cost treatment
    • 3.4. Market Trends
      • 3.4.1. Adopting of dogs as pets is a popular trend across the world
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Human Rabies Treatment -, by Type, Application, Distribution Channel and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Human Rabies Treatment - (Value)
      • 5.2.1. Global Human Rabies Treatment - by: Type (Value)
        • 5.2.1.1. Vero Cell Rabies Vaccine
        • 5.2.1.2. BHK
        • 5.2.1.3. Chick Embryo Cell Rabies Vaccine
        • 5.2.1.4. Others
      • 5.2.2. Global Human Rabies Treatment - by: Application (Value)
        • 5.2.2.1. Pre-Exposure Prophylaxis
        • 5.2.2.2. Post-Exposure Prophylaxis
      • 5.2.3. Global Human Rabies Treatment - by: Distribution Channel (Value)
        • 5.2.3.1. Hospital pharmacies
        • 5.2.3.2. Retail pharmacies
        • 5.2.3.3. E-commerce
      • 5.2.4. Global Human Rabies Treatment - Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Human Rabies Treatment - (Price)
      • 5.3.1. Global Human Rabies Treatment - by: Type (Price)
  • 6. Human Rabies Treatment -: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi-Pasteur (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Hissen (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Biological E Ltd. (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cadila Healthcare (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Grifols S.A. (Spain)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Kamada Ltd (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Kedrion S.p.A. (Italy)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Serum institute (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Chengda (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Human Rabies Treatment - Sale, by Type, Application, Distribution Channel and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Human Rabies Treatment - (Value)
      • 7.2.1. Global Human Rabies Treatment - by: Type (Value)
        • 7.2.1.1. Vero Cell Rabies Vaccine
        • 7.2.1.2. BHK
        • 7.2.1.3. Chick Embryo Cell Rabies Vaccine
        • 7.2.1.4. Others
      • 7.2.2. Global Human Rabies Treatment - by: Application (Value)
        • 7.2.2.1. Pre-Exposure Prophylaxis
        • 7.2.2.2. Post-Exposure Prophylaxis
      • 7.2.3. Global Human Rabies Treatment - by: Distribution Channel (Value)
        • 7.2.3.1. Hospital pharmacies
        • 7.2.3.2. Retail pharmacies
        • 7.2.3.3. E-commerce
      • 7.2.4. Global Human Rabies Treatment - Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Human Rabies Treatment - (Price)
      • 7.3.1. Global Human Rabies Treatment - by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Human Rabies Treatment -: by Type(USD Million)
  • Table 2. Human Rabies Treatment - Vero Cell Rabies Vaccine , by Region USD Million (2016-2021)
  • Table 3. Human Rabies Treatment - BHK , by Region USD Million (2016-2021)
  • Table 4. Human Rabies Treatment - Chick Embryo Cell Rabies Vaccine , by Region USD Million (2016-2021)
  • Table 5. Human Rabies Treatment - Others , by Region USD Million (2016-2021)
  • Table 6. Human Rabies Treatment -: by Application(USD Million)
  • Table 7. Human Rabies Treatment - Pre-Exposure Prophylaxis , by Region USD Million (2016-2021)
  • Table 8. Human Rabies Treatment - Post-Exposure Prophylaxis , by Region USD Million (2016-2021)
  • Table 9. Human Rabies Treatment -: by Distribution Channel(USD Million)
  • Table 10. Human Rabies Treatment - Hospital pharmacies , by Region USD Million (2016-2021)
  • Table 11. Human Rabies Treatment - Retail pharmacies , by Region USD Million (2016-2021)
  • Table 12. Human Rabies Treatment - E-commerce , by Region USD Million (2016-2021)
  • Table 13. South America Human Rabies Treatment -, by Country USD Million (2016-2021)
  • Table 14. South America Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 15. South America Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 16. South America Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 17. Brazil Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 18. Brazil Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 19. Brazil Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 20. Argentina Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 21. Argentina Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 22. Argentina Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 23. Rest of South America Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 24. Rest of South America Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 25. Rest of South America Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 26. Asia Pacific Human Rabies Treatment -, by Country USD Million (2016-2021)
  • Table 27. Asia Pacific Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 28. Asia Pacific Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 29. Asia Pacific Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 30. China Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 31. China Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 32. China Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 33. Japan Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 34. Japan Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 35. Japan Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 36. India Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 37. India Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 38. India Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 39. South Korea Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 40. South Korea Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 41. South Korea Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 42. Taiwan Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 43. Taiwan Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 44. Taiwan Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 45. Australia Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 46. Australia Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 47. Australia Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 48. Rest of Asia-Pacific Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 49. Rest of Asia-Pacific Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 50. Rest of Asia-Pacific Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 51. Europe Human Rabies Treatment -, by Country USD Million (2016-2021)
  • Table 52. Europe Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 53. Europe Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 54. Europe Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 55. Germany Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 56. Germany Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 57. Germany Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 58. France Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 59. France Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 60. France Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 61. Italy Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 62. Italy Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 63. Italy Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 64. United Kingdom Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 65. United Kingdom Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 66. United Kingdom Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 67. Netherlands Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 68. Netherlands Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 69. Netherlands Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 70. Rest of Europe Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 71. Rest of Europe Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 72. Rest of Europe Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 73. MEA Human Rabies Treatment -, by Country USD Million (2016-2021)
  • Table 74. MEA Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 75. MEA Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 76. MEA Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 77. Middle East Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 78. Middle East Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 79. Middle East Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 80. Africa Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 81. Africa Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 82. Africa Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 83. North America Human Rabies Treatment -, by Country USD Million (2016-2021)
  • Table 84. North America Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 85. North America Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 86. North America Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 87. United States Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 88. United States Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 89. United States Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 90. Canada Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 91. Canada Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 92. Canada Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 93. Mexico Human Rabies Treatment -, by Type USD Million (2016-2021)
  • Table 94. Mexico Human Rabies Treatment -, by Application USD Million (2016-2021)
  • Table 95. Mexico Human Rabies Treatment -, by Distribution Channel USD Million (2016-2021)
  • Table 96. Human Rabies Treatment -: by Type(USD/Units)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Human Rabies Treatment -: by Type(USD Million)
  • Table 108. Human Rabies Treatment - Vero Cell Rabies Vaccine , by Region USD Million (2022-2027)
  • Table 109. Human Rabies Treatment - BHK , by Region USD Million (2022-2027)
  • Table 110. Human Rabies Treatment - Chick Embryo Cell Rabies Vaccine , by Region USD Million (2022-2027)
  • Table 111. Human Rabies Treatment - Others , by Region USD Million (2022-2027)
  • Table 112. Human Rabies Treatment -: by Application(USD Million)
  • Table 113. Human Rabies Treatment - Pre-Exposure Prophylaxis , by Region USD Million (2022-2027)
  • Table 114. Human Rabies Treatment - Post-Exposure Prophylaxis , by Region USD Million (2022-2027)
  • Table 115. Human Rabies Treatment -: by Distribution Channel(USD Million)
  • Table 116. Human Rabies Treatment - Hospital pharmacies , by Region USD Million (2022-2027)
  • Table 117. Human Rabies Treatment - Retail pharmacies , by Region USD Million (2022-2027)
  • Table 118. Human Rabies Treatment - E-commerce , by Region USD Million (2022-2027)
  • Table 119. South America Human Rabies Treatment -, by Country USD Million (2022-2027)
  • Table 120. South America Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 121. South America Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 122. South America Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 123. Brazil Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 124. Brazil Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 125. Brazil Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 126. Argentina Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 127. Argentina Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 128. Argentina Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 129. Rest of South America Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 130. Rest of South America Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 131. Rest of South America Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 132. Asia Pacific Human Rabies Treatment -, by Country USD Million (2022-2027)
  • Table 133. Asia Pacific Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 134. Asia Pacific Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 135. Asia Pacific Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 136. China Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 137. China Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 138. China Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 139. Japan Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 140. Japan Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 141. Japan Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 142. India Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 143. India Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 144. India Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 145. South Korea Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 146. South Korea Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 147. South Korea Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 148. Taiwan Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 149. Taiwan Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 150. Taiwan Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 151. Australia Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 152. Australia Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 153. Australia Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 154. Rest of Asia-Pacific Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 155. Rest of Asia-Pacific Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 156. Rest of Asia-Pacific Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 157. Europe Human Rabies Treatment -, by Country USD Million (2022-2027)
  • Table 158. Europe Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 159. Europe Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 160. Europe Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 161. Germany Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 162. Germany Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 163. Germany Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 164. France Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 165. France Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 166. France Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 167. Italy Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 168. Italy Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 169. Italy Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 170. United Kingdom Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 171. United Kingdom Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 172. United Kingdom Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 173. Netherlands Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 174. Netherlands Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 175. Netherlands Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 176. Rest of Europe Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 177. Rest of Europe Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 178. Rest of Europe Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 179. MEA Human Rabies Treatment -, by Country USD Million (2022-2027)
  • Table 180. MEA Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 181. MEA Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 182. MEA Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 183. Middle East Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 184. Middle East Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 185. Middle East Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 186. Africa Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 187. Africa Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 188. Africa Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 189. North America Human Rabies Treatment -, by Country USD Million (2022-2027)
  • Table 190. North America Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 191. North America Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 192. North America Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 193. United States Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 194. United States Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 195. United States Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 196. Canada Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 197. Canada Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 198. Canada Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 199. Mexico Human Rabies Treatment -, by Type USD Million (2022-2027)
  • Table 200. Mexico Human Rabies Treatment -, by Application USD Million (2022-2027)
  • Table 201. Mexico Human Rabies Treatment -, by Distribution Channel USD Million (2022-2027)
  • Table 202. Human Rabies Treatment -: by Type(USD/Units)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Human Rabies Treatment -: by Type USD Million (2016-2021)
  • Figure 5. Global Human Rabies Treatment -: by Application USD Million (2016-2021)
  • Figure 6. Global Human Rabies Treatment -: by Distribution Channel USD Million (2016-2021)
  • Figure 7. South America Human Rabies Treatment - Share (%), by Country
  • Figure 8. Asia Pacific Human Rabies Treatment - Share (%), by Country
  • Figure 9. Europe Human Rabies Treatment - Share (%), by Country
  • Figure 10. MEA Human Rabies Treatment - Share (%), by Country
  • Figure 11. North America Human Rabies Treatment - Share (%), by Country
  • Figure 12. Global Human Rabies Treatment -: by Type USD/Units (2016-2021)
  • Figure 13. Global Human Rabies Treatment - share by Players 2021 (%)
  • Figure 14. Global Human Rabies Treatment - share by Players (Top 3) 2021(%)
  • Figure 15. Global Human Rabies Treatment - share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Novartis (Switzerland) Revenue: by Geography 2021
  • Figure 19. Sanofi-Pasteur (France) Revenue, Net Income and Gross profit
  • Figure 20. Sanofi-Pasteur (France) Revenue: by Geography 2021
  • Figure 21. Hissen (China) Revenue, Net Income and Gross profit
  • Figure 22. Hissen (China) Revenue: by Geography 2021
  • Figure 23. Biological E Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 24. Biological E Ltd. (India) Revenue: by Geography 2021
  • Figure 25. Cadila Healthcare (India) Revenue, Net Income and Gross profit
  • Figure 26. Cadila Healthcare (India) Revenue: by Geography 2021
  • Figure 27. Grifols S.A. (Spain) Revenue, Net Income and Gross profit
  • Figure 28. Grifols S.A. (Spain) Revenue: by Geography 2021
  • Figure 29. Kamada Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 30. Kamada Ltd (Israel) Revenue: by Geography 2021
  • Figure 31. Kedrion S.p.A. (Italy) Revenue, Net Income and Gross profit
  • Figure 32. Kedrion S.p.A. (Italy) Revenue: by Geography 2021
  • Figure 33. Serum institute (India) Revenue, Net Income and Gross profit
  • Figure 34. Serum institute (India) Revenue: by Geography 2021
  • Figure 35. Chengda (United States) Revenue, Net Income and Gross profit
  • Figure 36. Chengda (United States) Revenue: by Geography 2021
  • Figure 37. Global Human Rabies Treatment -: by Type USD Million (2022-2027)
  • Figure 38. Global Human Rabies Treatment -: by Application USD Million (2022-2027)
  • Figure 39. Global Human Rabies Treatment -: by Distribution Channel USD Million (2022-2027)
  • Figure 40. South America Human Rabies Treatment - Share (%), by Country
  • Figure 41. Asia Pacific Human Rabies Treatment - Share (%), by Country
  • Figure 42. Europe Human Rabies Treatment - Share (%), by Country
  • Figure 43. MEA Human Rabies Treatment - Share (%), by Country
  • Figure 44. North America Human Rabies Treatment - Share (%), by Country
  • Figure 45. Global Human Rabies Treatment -: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Novartis (Switzerland)
  • Sanofi-Pasteur (France)
  • Hissen (China)
  • Biological E Ltd. (India)
  • Cadila Healthcare (India)
  • Grifols S.A. (Spain)
  • Kamada Ltd (Israel)
  • Kedrion S.p.A. (Italy)
  • Serum institute (India)
  • Chengda (United States)
Additional players considered in the study are as follows:
Yisheng (China) , Prcmise (United States) , VACN (United States) ,
Select User Access Type

Key Highlights of Report


Mar 2024 227 Pages 89 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Human Rabies Treatment - Market Quantitative research analysis
Global Human Rabies Treatment - Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Human Rabies Treatment - market are Novartis (Switzerland), Sanofi-Pasteur (France), Hissen (China), Biological E Ltd. (India), Cadila Healthcare (India), Grifols S.A. (Spain), Kamada Ltd (Israel), Kedrion S.p.A. (Italy), Serum institute (India) and Chengda (United States), to name a few.
"Adopting of dogs as pets is a popular trend across the world" is seen as one of major influencing trends for Human Rabies Treatment - Market during projected period 2021-2027.
Vero Cell Rabies Vaccine segment in Global market to hold robust market share owing to "Increasing number of patient demand for treatment increases".

Know More About Global Human Rabies Treatment - Market Report?

Have a Query? Click Here

Other Related Reports

Fibrate Drugs Comprehensive Study by Type (Gemfibrozil, Lofibrate, Fenofibric Acids, Fenofibrates), End users (Hospitals, Homecare, Specialty clinics, Others), Distribution Channel (Hospital pharmacy...
$ 3350
Portal Hypertension Drugs Comprehensive Study by Type (Prehepatic, Intrahepatic, Posthepatic), Treatment (Endoscopic Therapy, Surgery, Radiology, Others), Drug Class (Vasoconstrictors, Vasodilators, ...
$ 3450
Vaginitis Drug Comprehensive Study by Drugs (Nitro Imidazole Compounds, Lincosamide Antibiotics, Triazoles, Imidazoles), Schedule of Drug (Rx, OTC), Route of Adminstration (Oral, Cutaneous, Vaginal),...
$ 3650
Penicillin Drugs Comprehensive Study by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other), Bacteria (Streptococcus pneumonia, Listeria, Neisseria gonorrhoea, Clo...
$ 3750
At-Home Health Testing Comprehensive Study by Usage (Disposable, Reusable), Distribution Channel (Online {Brand Website, E-Commerce Website}, Offline {Retail Pharmacies, Drug Stores, Supermarket/Hype...
$ 3750
Clenbuterol Comprehensive Study by Application (Asthma, Chronic Obstructive Pulmonary Disease (COPD)), Forms (Tablet, Inhaler Form), Side Effect (Anxiety, Shaking, Headaches, Abnormal Sweating), Dis...
$ 3800